OR13D1 Antibody

What is OR13D1 and why is it studied in research contexts?

OR13D1 (Olfactory Receptor, Family 13, Subfamily D, Member 1) is a G protein-coupled receptor involved in olfactory signaling pathways. Research interest stems from its potential roles beyond olfaction, including possible involvement in cellular processes outside the nasal epithelium. The protein has a calculated molecular weight of approximately 39 kDa, though it is commonly observed at approximately 72 kDa in western blot applications, suggesting post-translational modifications . Antibodies against OR13D1 serve as critical tools for investigating its expression patterns, localization, and potential functions in various tissues and disease states.

What are the available types of OR13D1 antibodies and their optimal applications?

Multiple OR13D1 antibodies are available with varying characteristics that determine their suitability for specific applications. Most commercially available OR13D1 antibodies are polyclonal antibodies raised in rabbits, though mouse-host polyclonal options also exist . These antibodies are validated for various applications including Western Blotting (WB), Enzyme-Linked Immunosorbent Assay (ELISA), Immunocytochemistry (ICC), and Immunofluorescence (IF) . The choice depends on experimental requirements, with some antibodies targeting specific epitopes such as the C-terminal region (AA 276-304) while others recognize different portions of the protein .

What are the recommended protocols for OR13D1 antibody storage and handling?

For optimal preservation of antibody activity, OR13D1 antibodies should be stored at -20°C for long-term storage (up to one year). For frequent use and short-term storage, maintaining the antibody at 4°C for up to one month is recommended . Multiple freeze-thaw cycles should be avoided as they can compromise antibody quality and performance . Most commercial OR13D1 antibodies are provided in buffer solutions containing stabilizers such as glycerol, BSA, and sodium azide to maintain antibody integrity . The specific formulation varies by manufacturer but typically includes PBS with 50% glycerol, 0.5% BSA, and 0.02% sodium azide .

What species reactivity should be considered when selecting OR13D1 antibodies?

When designing experiments, species reactivity is a critical consideration. Available OR13D1 antibodies demonstrate varied cross-reactivity profiles:

Researchers should select antibodies based on their experimental model organism and validate cross-reactivity when working with species not explicitly listed by manufacturers .

What considerations are important for immunohistochemical applications of OR13D1 antibodies?

For immunohistochemical applications, protocol optimization is particularly important. The Prestige Antibody HPA055921 has been specifically validated for immunohistochemistry with recommended dilutions of 1:20 to 1:50 . When performing immunohistochemistry with OR13D1 antibodies, researchers should consider:

• Fixation method: Paraformaldehyde fixation (4%) is generally preferred over methanol for membrane proteins like OR13D1

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) typically improves staining quality

• Background reduction: Extended blocking (1-2 hours) with serum from the species of the secondary antibody

• Signal amplification: Consider using biotin-streptavidin systems for low-abundance targets

• Validation controls: Include tissues known to express OR13D1 as positive controls, alongside antibody omission controls

The Human Protein Atlas project has extensively characterized certain OR13D1 antibodies across hundreds of normal and disease tissues, providing valuable reference data for expected staining patterns .

How can researchers verify OR13D1 antibody specificity for their experiments?

Antibody specificity validation is a critical step in experimental design. Several approaches should be considered:

• Peptide competition assays: Pre-incubating the antibody with its immunizing peptide should abolish specific staining. Some manufacturers offer blocking peptides derived from the immunogen .

• Knockout/knockdown validation: Testing the antibody in OR13D1 knockout tissues or knockdown cell lines provides rigorous validation.

• Multiple antibody concordance: Using different antibodies targeting distinct epitopes of OR13D1 to confirm consistent staining patterns.

• Recombinant protein testing: Some OR13D1 antibodies have been validated against arrays of 364 human recombinant protein fragments to ensure minimal cross-reactivity .

• Mass spectrometry correlation: For advanced validation, immunoprecipitation followed by mass spectrometry can confirm target identity.

Antibody specificity should be established independently for each experimental application (WB, IHC, ICC), as performance can vary considerably between applications.

What are effective strategies for troubleshooting weak or absent OR13D1 signal in Western blots?

When encountering weak or absent signal in Western blot applications, several methodological approaches can be implemented:

• Sample preparation optimization: OR13D1 is a membrane protein that may require specialized lysis buffers containing appropriate detergents (1-2% Triton X-100 or 0.5-1% SDS) to efficiently solubilize the protein.

• Protein denaturation conditions: Heat samples at 70°C rather than 95°C to prevent aggregation common with membrane proteins.

• Loading quantity adjustment: Increase protein loading to 50-80 μg for tissues with low OR13D1 expression.

• Transfer conditions: Use lower methanol concentrations (10%) in transfer buffer and extend transfer time for larger proteins.

• Antibody concentration: If using dilutions at the higher end of the recommended range (e.g., 1:2000), try more concentrated preparations (1:500) .

• Signal enhancement: Consider using high-sensitivity chemiluminescent substrates or signal amplification systems.

• Exposure time: Extend exposure time incrementally to detect low-abundance signals.

Researchers should systematically test these variables while maintaining appropriate controls to identify optimal conditions for their specific experimental system.

How can researchers integrate OR13D1 antibodies in multiplex immunofluorescence experiments?

For advanced multiplex immunofluorescence applications, careful consideration of several factors is required:

• Antibody species selection: When designing panels, select primary antibodies from different host species to avoid cross-reactivity of secondary antibodies. The availability of OR13D1 antibodies from both rabbit and mouse hosts facilitates multiplex design .

• Conjugated antibody options: Consider using directly conjugated OR13D1 antibodies (APC, Biotin, or FITC conjugates are available) to simplify multiplex panels .

• Sequential staining protocols: For challenging combinations, implement sequential staining with complete blocking between rounds.

• Spectral unmixing: For experiments with overlapping fluorophore spectra, apply computational spectral unmixing during image analysis.

• Antibody validation: Validate each antibody individually before combining in multiplex experiments to ensure specificity is maintained.

When designing multiplex panels, researchers should first establish the localization pattern of OR13D1 using single-stain experiments before proceeding to more complex co-localization studies.

What are the critical considerations when selecting secondary antibodies for OR13D1 detection?

Secondary antibody selection significantly impacts experimental outcomes when working with OR13D1 antibodies:

• Host species matching: Select secondary antibodies that specifically recognize the host species of the OR13D1 primary antibody (typically anti-rabbit or anti-mouse IgG) .

• Cross-adsorption requirements: For multiplex applications, use highly cross-adsorbed secondary antibodies to minimize non-specific binding.

• Detection system compatibility: Choose secondary antibodies appropriate for the detection system (HRP-conjugated for chemiluminescence, fluorophore-conjugated for fluorescence imaging).

• Sensitivity considerations: For low-abundance targets, consider signal amplification systems like biotin-streptavidin.

• Isotype specificity: Match the secondary antibody to the isotype of the primary antibody (typically IgG for the available OR13D1 antibodies) .

Appropriate dilution of secondary antibodies is also critical, with typical ranges from 1:1000 to 1:5000 depending on the detection system employed.

How should researchers interpret molecular weight variations in OR13D1 Western blot results?

Interpreting OR13D1 Western blot results requires careful consideration of molecular weight variations:

• Expected versus observed weight: The calculated molecular weight of OR13D1 is approximately 39 kDa, but it is frequently observed at approximately 72 kDa in Western blot applications .

• Post-translational modifications: This discrepancy is likely due to glycosylation or other post-translational modifications common to G protein-coupled receptors.

• Multiple bands interpretation: The presence of multiple bands may indicate:

  • Different glycosylation states

  • Proteolytic processing

  • Alternative splicing variants

  • Protein dimers or oligomers resistant to denaturation

• Validation approaches: To confirm band specificity:

  • Peptide competition assays can identify specific bands

  • Deglycosylation experiments with PNGase F may resolve multiple bands to a single species

  • Cross-validation with multiple antibodies targeting different epitopes

Researchers should document the molecular weight(s) observed in their specific experimental system and provide appropriate evidence for band specificity in publications.

What are the best practices for quantifying OR13D1 expression in comparative studies?

For rigorous quantification of OR13D1 expression in comparative studies:

• Normalization strategy: Always normalize OR13D1 signal to appropriate loading controls:

  • Housekeeping proteins (β-actin, GAPDH) for whole cell lysates

  • Na+/K+ ATPase or calnexin for membrane fractions

• Linear dynamic range: Validate that signal detection remains within the linear dynamic range of the detection system to ensure accurate quantification.

• Technical replicates: Include a minimum of three technical replicates per biological sample.

• Biological replicates: Design experiments with sufficient biological replicates (typically n≥3) for statistical analysis.

• Densitometry protocols: Use consistent analysis parameters in densitometry software:

  • Background subtraction methods

  • Region of interest selection

  • Integration parameters

• Statistical analysis: Apply appropriate statistical tests based on data distribution and experimental design.

For immunohistochemical quantification, consider employing digital image analysis with defined intensity thresholds and reporting both staining intensity and percentage of positive cells.

How might single-cell approaches enhance OR13D1 expression analysis?

Emerging single-cell technologies offer powerful new approaches for investigating OR13D1 expression patterns:

• Single-cell RNA sequencing can reveal cell-type-specific expression patterns of OR13D1 mRNA, potentially identifying novel cell populations expressing this receptor outside olfactory tissues.

• Mass cytometry (CyTOF) with metal-conjugated OR13D1 antibodies enables high-dimensional analysis of protein expression across heterogeneous cell populations.

• Spatial transcriptomics approaches can map OR13D1 expression within complex tissue architectures while preserving spatial context.

• CODEX multiplexed imaging allows simultaneous visualization of OR13D1 alongside dozens of other markers in the same tissue section.

These approaches require careful antibody validation but offer unprecedented resolution for understanding OR13D1 biology in normal and disease states.

What considerations are important when designing CRISPR-based validation experiments for OR13D1 antibodies?

CRISPR-based approaches represent the gold standard for antibody validation:

• Guide RNA design: Target early exons of OR13D1 to ensure complete protein knockout.

• Control selection: Include both wild-type and non-targeting guide controls.

• Clonal expansion considerations: Generate multiple independent knockout clones to control for clonal effects.

• Validation strategy:

  • Confirm knockout at genomic level (sequencing)

  • Verify mRNA loss (RT-qPCR)

  • Demonstrate protein absence using the antibody under validation

• Knockout cell line applications:

  • Use as negative controls in all experimental applications

  • Employ for determining antibody specificity across applications (WB, IF, IHC)

  • Identify non-specific binding that persists in knockout samples

CRISPR validation is particularly valuable for OR13D1 antibodies where specificity concerns may exist due to sequence similarity with other olfactory receptor family members.